Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Navigating New & Crowded ADC Clinical Indications to Achieve Differentiation & Maximize Benefit to Patients

Navigating New & Crowded ADC Clinical Indications to Achieve Differentiation & Maximize Benefit to Patients

10:58 am - Wednesday 14th October 2026

Speakers:

Jutta Deckert

Jutta Deckert

Vice President, Research & Development

Iksuda Therapeutics